Marshall Urist, EVP, Research & Investments at Royalty Pharma plc (RPRX), sold 83,150 shares at $39.90 ($3.3M) on 2025-12-01, disclosed to the SEC on 2025-12-03.
Scheduled sale ($3.3M) by EVP, Research & Investments under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $39.90 | 18,242 | $728K | 21.9% |
| 2 | $39.90 | 18,242 | $728K | 21.9% |
| 3 | $39.93 | 23,333 | $932K | 28.1% |
| 4 | $39.93 | 23,333 | $932K | 28.1% |
| Total | $39.92 avg | 83,150 | $3.3M | 100% |
| Filing → |
| RPRX | SELL | 2026-07-02 | $508K | — | Filing → |
| RPRX | SELL | 2026-06-25 | $502K | — | Filing → |
| RPRX | SELL | 2026-05-21 | $722K | — | Filing → |